靶点- |
作用机制- |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2010-12-01 |
靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2005-11-18 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
非在研适应症- |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅲ Clinical Study to Evaluate Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Adults
To Evaluate Efficacy and Safety of AYP-101 S.C injection for the Reduction of Submental Fat in Adults
A Randomized, Double-blind, Placebo-controlled, Single Center and Single Dose Phase Ⅰ Study to Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of AYP-101 S.C. Injection in Healthy Subjects
To Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of AYP-101 S.C. injection in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Single Center and Single Dose
A Single Center, Randomized, Placebo Controlled Phase Ⅱ Study to Determine the Dosing Interval and the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
To determine the dosing interval, optimal dose, evaluate safety, and efficacy of AYP-101 S.C injection for the reduction of Submental Fat (SMF).
100 项与 Ami Pharm Co., Ltd. 相关的临床结果
0 项与 Ami Pharm Co., Ltd. 相关的专利(医药)
100 项与 Ami Pharm Co., Ltd. 相关的药物交易
100 项与 Ami Pharm Co., Ltd. 相关的转化医学